Halozyme Therapeutics Inc

Halozyme CEO’s $1.4M share purchase signals confidence amid strong earnings and a $1 bn buy‑back program, hinting at upside for investors.

Halozyme insider buying signals confidence amid new GSK and Oruka drug‑delivery deals, hinting at potential upside for investors.

Halozyme insider sales trend: Connaughton Bernadette’s latest 1,625‑share sale hints at cautious leadership amid upcoming CFO hire and earnings. Learn the implications.

CEO Tor Helen’s $12.07 buy of 10,000 Halozyme shares signals insider confidence in the company’s enzyme‑conjugated platform and its new Australian partnership, hinting at potential upside despite market volatility.

CEO Tor Helen’s $12.07 insider buy of 20 000 Halozyme shares signals deep confidence in its hyaluronidase tech—an attractive “buy‑low” move without dilution.

Insider buying by Halozyme’s COO signals confidence in its hyaluronidase pipeline and future growth, despite a recent share price dip.

Halozyme insider buying surge signals strong confidence in future growth, as COO and executives pile up options and performance‑stock units ahead of Q4 earnings.

Halozyme insider buying signals confidence ahead of earnings—learn why the CEO’s new shares hint at growth in the biopharma pipeline.